Get the Stockscreener App
2.04
3.32%
-0.07
Calcimedica Inc stock is traded at $2.04, with a volume of 35,965.
It is down -3.32% in the last 24 hours and down -15.70% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
See More
Previous Close:
$2.11
Open:
$2.1
24h Volume:
35,965
Relative Volume:
1.31
Market Cap:
$27.50M
Revenue:
-
Net Income/Loss:
$-13.59M
P/E Ratio:
-1.8889
EPS:
-1.08
Net Cash Flow:
$-19.79M
1W Performance:
+6.25%
1M Performance:
-15.70%
6M Performance:
-50.72%
1Y Performance:
-39.82%
1-Day Range:
$2.01
$2.15
1-Week Range:
$1.8329
$2.15
52-Week Range:
$1.8329
$6.265
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
2.04 | 27.50M | 0 | -13.59M | -19.79M | -1.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Calcimedica Inc Stock (CALC) Latest News
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
Can CalciMedica's Auxora Save Lives? New Data Shows 62.7% Lower Death Rate in Critical COVID-AKI Patients - StockTitan
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors - Victoria Advocate
CalciMedica announces board changes By Investing.com - Investing.com Australia
CalciMedica appoints new director amid clinical trials By Investing.com - Investing.com Nigeria
CalciMedica announces board changes - Investing.com
CalciMedica appoints new director amid clinical trials - Investing.com
CalciMedica Announces Board Changes and New Appointment - TipRanks
CalciMedica, Inc. (NASDAQ:CALC) Shares Acquired by Geode Capital Management LLC - Defense World
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - The Eastern Progress Online
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - The Eastern Progress Online
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Graybug Vision stock hits 52-week low at $2.65 amid market challenges - Investing.com Canada
CalciMedica Announces Presentations at Upcoming Medical Meetings - The Eastern Progress Online
CalciMedica director Fred Middleton buys $12,720 in stock By Investing.com - Investing.com Canada
CalciMedica director Fred Middleton buys $12,720 in stock - Investing.com
Atria Investments Inc Purchases 15,296 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica to Present CRAC Channel Therapy Updates at Piper Sandler Healthcare Conference | CALC Stock News - StockTitan
Insiders Bet Big on These Small Cap Stocks - MSN
CalciMedica Launches $10M+ Public Stock Offering BIOPHARMA: Propelling Calcium-Based Drug Platform By JENNIFER KASTNER - San Diego Business Journal
CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright - Defense World
Bkv Corp (BKV-N) QuotePress Release - The Globe and Mail
CalciMedica reports Q3 EPS (50c), consensus (50c) - TipRanks
CalciMedica's Auxora Shows 100% Risk Reduction in Respiratory Failure, Extends Cash Runway | CALC Stock News - StockTitan
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanderling Venture Partners VI | 10% Owner |
Nov 01 '24 |
Buy |
3.75 |
86,867 |
325,751 |
814,300 |
| Sanderling Venture Partners VI | 10% Owner |
Nov 01 '24 |
Buy |
3.75 |
877 |
3,289 |
22,479 |
| MIDDLETON FRED A | Director |
Nov 01 '24 |
Buy |
3.75 |
87,744 |
329,040 |
814,300 |
| MIDDLETON FRED A | Director |
Nov 01 '24 |
Buy |
3.75 |
20,000 |
75,000 |
31,714 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER |
Nov 01 '24 |
Buy |
3.75 |
20,000 |
75,000 |
130,926 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Nov 01 '24 |
Buy |
3.75 |
53,333 |
199,999 |
164,706 |
| WILSON ROBERT N | Director |
Nov 01 '24 |
Buy |
3.75 |
53,333 |
199,999 |
417,529 |
| Dunn Michael J. | President and COO |
Sep 09 '24 |
Option Exercise |
1.39 |
11,761 |
16,348 |
11,761 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER |
Aug 27 '24 |
Buy |
4.19 |
1,000 |
4,190 |
110,926 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 23 '24 |
Buy |
3.57 |
5,000 |
17,867 |
46,894 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):